Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CAT 2003

Next Previous
X
Search
Drug Profile

CAT 2003

Alternative Names: CAT-2003; Niacin-eicosapentaenoic acid conjugate

Latest Information Update: 09 Sep 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Catabasis Pharmaceuticals
  • Developer Astria Therapeutics
  • Class Antihyperlipidaemics; Eicosanoids; Lipids; Nicotinic acids; Omega 3 fatty acids; Peripheral vasodilators; Small molecules; Vitamins
  • Mechanism of Action Sterol regulatory element binding protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Hypercholesterolaemia; Hyperlipoproteinaemia type I; Hypertriglyceridaemia; Non-alcoholic steatohepatitis

Most Recent Events

  • 08 Sep 2021 Catabasis Pharmaceuticals is now called Astria Therapeutics
  • 28 Apr 2020 No recent reports of development identified for preclinical development in Non-alcoholic-steatohepatitis in USA
  • 24 May 2016 No development reported - Phase-II for Hypercholesterolaemia (Adjunctive treatment) in USA, Canada (PO)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top